Clinical trial
Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine
NCT00482027 · International AIDS Vaccine Initiative, Other · Completed
Key facts
| NCT number | NCT00482027 |
|---|---|
| Title | Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine |
| Official title | A Phase 1 Randomized, Placebo-controlled, Double-blind Dose-escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine |
| Acronym | A001 |
| Lead sponsor | International AIDS Vaccine Initiative, Other |
| Collaborators | Targeted Genetics Corporation Industry Children's Hospital of Philadelphia Nationwide Children's Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Biological |
| Interventions | tgAAC09 |
| Enrollment | 80 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Jun 4, 2007 |
| Last update posted | Jan 16, 2013 |
| Countries | Belgium, Germany, India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: